Document is current

Article History

Received: 25 July 2024

Accepted: 7 January 2025

First Online: 24 January 2025

Declarations

:

: The ERNEST-B study was approved by the Ethics Committee of the Medical Faculty of Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen (application number 297_17 Bc). The HaBCS was approved by the ethics committee at Hannover Medical School (No. 6079). GeparSepto (NCT01583426) and GeparOcto (NCT02125344) were multicenter trials, approved by the ethics committees/institutional review boards and the competent authority. Patients enrolled into the GeparSepto and GeparOcto studies provided informed consent. In the ERNEST-B and HaBCS studies, patient data were collected in accordance with the breast center certification requirements of the German Cancer Society. All experiments were performed in accordance with relevant guidelines and regulations.

: Not applicable.

: RE has received honoria from Roche, Eisai, and Novartis; has participated on advisory boards for Roche; and has received compensation for travel expenses from Novartis and Roche. PG has received honoraria from Novartis; financial support for symposia from Novartis, Roche, and PharmaMar; and compensation for travel expenses from discovering hands®. CCH has received honoraria from Roche. AH has received honoraria and compensation for travel expenses from BMS, MSD, Roche, AstraZeneca, AbbVie, Böhringer Ingelheim, Sysmex, Janssen, and Cepheid; has participated on advisory boards for BMS, MSD, Roche, AstraZeneca, AbbVie, Böhringer Ingelheim, Sysmex, Janssen, Cepheid, and NanoString; has received research funding from Janssen, Roche, Cepheid, and NanoString; and has provided expert testimony for NanoString. MPL has participated on advisory boards for AstraZeneca, MSD, Novartis, Pfizer, Eisai, Genomic Health, Tesaro, and Roche, and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac, and Eisai. PAF reports grants from Novartis, Cepheid, and BioNTech, and personal fees from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, AstraZeneca, MSDohme, Myelo Therapeutics, Macrogenics, Eisai, and Puma. All remaining authors have no conflicts of interest to disclose.